New eye gel could ease rosacea symptoms
NCT ID NCT07443202
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a gel called lotilaner for people with moderate to severe ocular rosacea, a condition causing red, irritated eyes. About 155 adults will receive either the gel or a placebo to see if it is safe and helps symptoms. The study is currently enrolling by invitation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lotilaner ophthalmic gel
- What this could lead to
- If it works, this could point toward a new treatment option for ocular rosacea, reducing redness and discomfort.
- What could go wrong
- This is an early Phase 2 study with only 155 participants, so results may not confirm effectiveness. Safety and tolerability are the main focus, and the gel may not work for everyone.
Why investors are watching
Tarsus Pharmaceuticals is running a phase 2 trial of lotilaner ophthalmic gel in 155 people with ocular rosacea, a condition with few approved treatments. For a small company, this readout tests whether its drug can ease symptoms and show enough promise to justify further development. A clear result matters because the company's value rests heavily on its pipeline.
If it works: A positive result could position lotilaner as a potential first-line treatment for ocular rosacea, opening a new market for the company. It might also strengthen Tarsus's pipeline and support its case for advancing the drug to later-stage trials.
If it fails: A failure or weak signal could set back the drug's development and hurt the company's prospects, since phase 2 trials often do not meet their goals. A delay in reporting results could also create uncertainty for investors.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 155 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years of age or older at the time of consent. * Has moderate to severe ocular rosacea * Use of acceptable methods of contraception * Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol Exclusion Criteria: * Patient taking a topical or other therapy which may affect the patients rosacea * Actively managed glaucoma or active ocular infection or ocular systemic disease * Have hypersensitivity to lotilaner or any of the formulation components * Are currently enrolled in an investigational drug or device study * Are currently pregnant or lactating or planning to become pregnant during the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ocular rosacea are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Site
Houston, Texas, 77027, United States
-
Site
Lynchburg, Virginia, 24502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.